Snakebite envenomation remains a significant global health concern, disproportionately affecting resource-limited regions and contributing to substantial morbidity and mortality. Antivenom therapy, first pioneered in the late 19th century, continues to serve as the cornerstone of treatment, yet production methods have changed little over the past century. Modern manufacturing involves refining polyclonal antibodies-typically derived from horses, sheep, or goats-through immunization, purification, and enzymatic modification to improve efficacy and safety. Despite these advances, challenges persist, including limited availability, high cost, species-specific efficacy, and risks of hypersensitivity reactions. Recent research has expanded beyond traditional serotherapy, exploring small-molecule inhibitors, monoclonal and recombinant antibodies, immunoglobulin Y-based therapeutics, and hybrid strategies to neutralize venom toxins with greater precision and scalability. Emerging agents such as varespladib and marimastat highlight the potential of targeted adjuncts to mitigate systemic and local effects of envenomation, whereas recombinant and engineered antibodies promise safer, more consistent, and more cost-effective solutions. Together these innovations aim to overcome long-standing barriers in antivenom development, offering renewed hope for effective, accessible, and equitable therapies. However, no single approach yet addresses all challenges, underscoring the need for continued multidisciplinary efforts to improve outcomes for envenomated patients worldwide.
Brandehoff et al. (Wed,) studied this question.